News
Having a child recipient and helping someone in need – especially if they knew them – were among the top reasons that people ...
Uplizna gains new indication; Vanrafia approved for proteinuria in IgAN; Erzofri now available for schizophrenia; setmelanotide shows promise in hypothalamic obesity; GLP-1RAs may reduce dementia risk ...
Amid all the volatility, some companies are proving resilient by performing much better than the market. Some of these look ...
Vanrafia' está indicado para la reducción de los niveles elevados de proteínas en la orina en nefropatía primaria por ...
Richard Lafayette, MD, FACP, Stanford University Medical Center, explains the significance of this second approval in a month ...
Amvuttra (vutrisiran) Transthyretin-directed small interfering RNA therapeutic Treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce ...
Swiss pharma giant Novartis (NOVN: VX) has announced a planned $23 billion investment over five years in US-based infrastructure, ensuring all key Novartis medicines for US patients will be made in ...
En una declaración reciente, el analista de Canaccord Genuity, Ed Nash, destacó los cambios dinámicos dentro del panorama de medicamentos para IgAN, mencionando la Aprobación Acelerada de la FDA para ...
As targeted treatments such as Tarpeyo (Calliditas), Filspari (Travere), Fabhalta (Novartis), and most recently Vanrafia (Novartis) enter the market, this research captures how patients are ...
As targeted treatments such as Tarpeyo (Calliditas), Filspari (Travere), Fabhalta (Novartis), and most recently Vanrafia (Novartis) enter the market, this research captures how patients are navigating ...
NEW HYDE PARK, N.Y., April 07, 2025 (GLOBE NEWSWIRE) -- CareMed, an independent specialty pharmacy, is in the Limited Distribution Network for Vanrafia â„¢ (atrasentan), for the reduction of proteinuria ...
The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia ® (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results